(S)-(-)-3-BROMOISOBUTYRIC ACID METHYL ESTER
Synonym(s):(−)-Methyl (S)-β-bromoisobutyrate
- CAS NO.:98190-85-3
- Empirical Formula: C5H9BrO2
- Molecular Weight: 181.03
- MDL number: MFCD00064487
- SAFETY DATA SHEET (SDS)
- Update Date: 2026-01-13 11:25:47
What is (S)-(-)-3-BROMOISOBUTYRIC ACID METHYL ESTER?
The Uses of (S)-(-)-3-BROMOISOBUTYRIC ACID METHYL ESTER
(?)-Methyl (S)-3-bromo-2-methylpropionate can be used:
- As a reference substrate in the alkylation reactions of vitamin B12 derivatives.
- As a starting material in the preparation of biologically significant 3-[(2H-1,2,4-benzothiadiazine-1,1-dioxide-3-yl)thio]-2-methylpropanoic acids.
Properties of (S)-(-)-3-BROMOISOBUTYRIC ACID METHYL ESTER
| Boiling point: | 97.5-98.5 °C62 mm Hg(lit.) |
| Density | 1.422 g/mL at 25 °C(lit.) |
| refractive index | n |
| Flash point: | 165 °F |
| storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C |
| form | clear liquid |
| color | Colorless to Almost colorless |
| optical activity | [α]20/D 23 to 16°, c = 5 neat |
| BRN | 1720832 |
| CAS DataBase Reference | 98190-85-3(CAS DataBase Reference) |
Safety information for (S)-(-)-3-BROMOISOBUTYRIC ACID METHYL ESTER
| Signal word | Warning |
| Pictogram(s) |
![]() Exclamation Mark Irritant GHS07 |
| GHS Hazard Statements |
H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
| Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P264:Wash hands thoroughly after handling. P264:Wash skin thouroughly after handling. P271:Use only outdoors or in a well-ventilated area. P280:Wear protective gloves/protective clothing/eye protection/face protection. P302+P352:IF ON SKIN: wash with plenty of soap and water. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for (S)-(-)-3-BROMOISOBUTYRIC ACID METHYL ESTER
New Products
Paroxetine Impurity G/Paroxetine Related Compound E 1-Aminocyclopentane carbonitrile (RS)-beta-Amino-beta-(4-bromophenyl)propionic acid N,N CARBONYL DIIMIDAZOLE 2-Amino-5-bromo-4-(trifluoromethyl)pyridine(RM for Indian lab) Benzyl (3R,4S)-3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate (R)-1-Benzyl-3-pyrrolidinecarbonitrile Betahistine EP Impurity C Cyclobenzaprine N-oxide/Citalopram Related Compound E Chlorthalidone Impurity I Carbamazepine EP Impurity G Sumatriptan Succinate USP Related Compound C 2,2'-(5-methyl-1,3-phenylene)-di(2-Methylpropionitrile) 4-Fluorothiophenol 1-methyl amino-2,4-dinitro benzene 5-Methyl-1,3-benzenediacetonitrile (R)-BoroLeu-(+)-Pinanediol-CF3COOH 4-(5-amino-1-methyl-1h-benzoimidazol-2-yl)-butyric acid isopropyl ester. 4-Bromo Benzylcyanide 3-Hydroxypropionitrile valeronitrile 3,4 Dimethoxy Benzylcyanide 3-chlorobenzyl cyanide 2-Chloro BenzylcyanideRelated products of tetrahydrofuran
![ETHYL 8-(BROMOMETHYL)-1,4-DIOXASPIRO[4.5]DECANE-8-CARBOXYLATE](https://img.chemicalbook.in/StructureFile/ChemBookStructure2/GIF/CB5464092.gif)





You may like
-
Methyl (S)-(-)-3-Bromoisobutyrate CAS 98190-85-3View Details
98190-85-3 -
(−)-Methyl (S)-3-bromo-2-methylpropionate CAS 98190-85-3View Details
98190-85-3 -
2847776-12-7 Sumatriptan Succinate USP Related Compound C NLT 95%View Details
2847776-12-7 -
1012886-75-7(HCl Salt)/69675-10-1(Freebase) Paroxetine Impurity G/Paroxetine Related Compound E NLT 95%View Details
1012886-75-7(HCl Salt)/69675-10-1(Freebase) -
3,4 Diethoxy Benzylcyanide 99%View Details
27472-21-5 -
Bromoacetaldehyde Dimethyl Acetal (stabilized with K2CO3)View Details
7252-83-7 -
157528-56-8 (R)-1-Benzyl-3-pyrrolidinecarbonitrile 98+View Details
157528-56-8 -
157528-56-8 (R)-1-Benzyl-3-pyrrolidinecarbonitrile 98+View Details
157528-56-8
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

